AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8602384 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonnephrotoxic chemotherapy
Number of subjects: 77
Study 8602384 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cancer)
Number of subjects: 77
Study 8602384 — intervention group
Group type: EXPERIMENTAL
Intervention: Age effect on pharmacokinetics
Number of subjects: 77
Study 8602384 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin dosing
Number of subjects: 77
Study 2669222 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose nebulised morphine (5 ml of morphine 1 mg/ml)
Number of subjects: 11
Study 2669222 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 11
Study 769773 — intervention group
Group type: EXPERIMENTAL
Intervention: Active electrosleep therapy
Number of subjects: 0
Study 769773 — intervention group
Group type: COMPARATOR
Intervention: Simulated treatment (placebo)
Number of subjects: 0
Study 31596174 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support program for glycemic management
Number of subjects: 0
Study 28647167 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY‐TT vaccine
Number of subjects: 94
Study 26081587 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of telmisartan
Number of subjects: 300
Study 26081587 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo
Number of subjects: 300
Study 23832086 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir gel
Number of subjects: 34
Study 23832086 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 34
Study 21528641 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of mosapride citrate
Number of subjects: 20
Study 21528641 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of mosapride citrate
Number of subjects: 20
Study 18648237 — intervention group
Group type: EXPERIMENTAL
Intervention: L4-L5 primary dorsal rami and S1-S3 lateral branch radiofrequency denervation using cooling-probe technology after a local anesthetic block
Number of subjects: 28
Study 18648237 — intervention group
Group type: COMPARATOR
Intervention: Placebo denervation after local anesthetic block
Number of subjects: 28
Study 18648237 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover group (patients who did not respond to placebo) treated with radiofrequency denervation using conventional technology
Number of subjects: 28
Study 18648237 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 28
Study 16424446 — intervention group
Group type: EXPERIMENTAL
Intervention: Transtracheal open ventilation
Number of subjects: 39
Study 16424446 — intervention group
Group type: COMPARATOR
Intervention: Conventional invasive ventilation
Number of subjects: 39
Study 12837869 — intervention group
Group type: EXPERIMENTAL
Intervention: Heptavalent pneumococcal conjugate vaccine (PCV)
Number of subjects: 45
Study 12837869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 10877005 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50 mg)
Number of subjects: 7
Study 10877005 — intervention group
Group type: COMPARATOR
Intervention: Citalopram (40 mg)
Number of subjects: 7
Study 10877005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 9413817 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher high-level questions
Number of subjects: 57
Study 9413817 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher elaboration of student ideas
Number of subjects: 57
Study 9413817 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher probing questions
Number of subjects: 57
Study 9413817 — intervention group
Group type: EXPERIMENTAL
Intervention: Student participation
Number of subjects: 57
Study 9413817 — intervention group
Group type: EXPERIMENTAL
Intervention: Student-to-student participation
Number of subjects: 57
Study 8493803 — intervention group
Group type: COMPARATOR
Intervention: Amino‐Mel hepa (Group A)
Number of subjects: 30
Study 8493803 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino‐Mel hepa + L‐valine (Group B)
Number of subjects: 30
Study 3522443 — intervention group
Group type: EXPERIMENTAL
Intervention: 1g of ambroxol for three days before surgery, on the day of the operation and for five days afterwards
Number of subjects: 40
Study 30264583 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart Glucose Manager (SGM) application
Number of subjects: 67
Study 30264583 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard methods of diabetes management)
Number of subjects: 67
Study 27662264 — intervention group
Group type: EXPERIMENTAL
Intervention: New oral liquid formulation combining guaifenesin, pseudoephedrine and hydrocodone
Number of subjects: 12
Study 27662264 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose oral liquid formulation (5 to 15 mL)
Number of subjects: 12
Study 27662264 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple dosing of oral liquid formulation
Number of subjects: 12
Study 27662264 — intervention group
Group type: EXPERIMENTAL
Intervention: New oral liquid formulation
Number of subjects: 12
Study 25546568 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation (SNM) with the InterStim® System
Number of subjects: 272
Study 23338666 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia
Number of subjects: 60
Study 23338666 — intervention group
Group type: COMPARATOR
Intervention: Femoral nerve block
Number of subjects: 60
Study 23092665 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous PPI followed by oral administration (group 2)
Number of subjects: 40
Study 23092665 — intervention group
Group type: COMPARATOR
Intervention: Oral PPIs alone (group 1)
Number of subjects: 40
Study 20021657 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral artesunate (AS) 2-5 mg/kg
Number of subjects: 91
Study 20021657 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral artesunate (AS)
Number of subjects: 91
Study 20021657 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin (DHA)
Number of subjects: 91
Study 20021657 — intervention group
Group type: COMPARATOR
Intervention: High-fat and high-caloric meal prior to drug administration
Number of subjects: 91
Study 20021657 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight
Number of subjects: 91
Study 18030711 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic angiogenesis (cell transplantation, gene therapy, application of growth factors)
Number of subjects: 0
Study 12547365 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength-Dexterity (S-D) test using a subset of 39 springs
Number of subjects: 42
Study 12547365 — intervention group
Group type: COMPARATOR
Intervention: Maximal pinch force values
Number of subjects: 42
Study 10924866 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) 1000 or 3000 mg
Number of subjects: 246
Study 10924866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study 8810671 — intervention group
Group type: EXPERIMENTAL
Intervention: Reumalex, a licensed over-the-counter herbal medicine
Number of subjects: 82
Study 8810671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 1605451 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide (DF) 400 mg i.v. given one hour prior to operation and twice daily for seven days postoperatively
Number of subjects: 1212
Study 1605451 — intervention group
Group type: COMPARATOR
Intervention: Calcium-heparin (CH) 0.2 ml (5000 U.I.) subcutaneously given one hour prior to operation and twice daily for seven days postoperatively
Number of subjects: 1212
Study 1605451 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide (DF)
Number of subjects: 1212
Study 1605451 — intervention group
Group type: COMPARATOR
Intervention: Calcium-heparin (CH)
Number of subjects: 1212
Study 1605451 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1212
Study 6420352 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release buccal nitroglycerin (23.4 mg daily)
Number of subjects: 21
Study 3716918 — intervention group
Group type: EXPERIMENTAL
Intervention: Four hypnotic sessions with a booster
Number of subjects: 63
Study 3716918 — intervention group
Group type: EXPERIMENTAL
Intervention: Two hypnotic sessions
Number of subjects: 63
Study 3716918 — intervention group
Group type: EXPERIMENTAL
Intervention: Two hypnotic and two behavioral sessions with a booster
Number of subjects: 63
Study 3716918 — intervention group
Group type: EXPERIMENTAL
Intervention: Four hypnotic sessions and a booster session (follow-up group)
Number of subjects: 63
Study 29166778 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic relaxation CD
Number of subjects: 21
Study 29166778 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study 26851251 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised progressive resistance training of the operated leg two days/week in addition to home‐based exercise five days/week for 10 weeks
Number of subjects: 37
Study 26851251 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training with increasing load from 12 repetition maximum to 8 repetition maximum over 10 weeks
Number of subjects: 37
Study 26851251 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Number of subjects: 37
Study 25708324 — intervention group
Group type: EXPERIMENTAL
Intervention: Divaza preparation, 12-week treatment course
Number of subjects: 0
Study 25708324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22130178 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone monotherapy
Number of subjects: 111
Study 22130178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 20456149 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Training (BT)
Number of subjects: 13
Study 18376267 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol alone
Number of subjects: 22
Study 18376267 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and fentanyl
Number of subjects: 22
Study 16724578 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (soft gelatin capsules containing a new self-nanoemulsifying formulation of cyclosporin A, 200 mg) after a fat-rich breakfast (Treatment A)
Number of subjects: 18
Study 16724578 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (Neoral, Novartis AG, Basel, Switzerland, 200 mg) after a fat-rich breakfast (Treatment B)
Number of subjects: 18
Study 16724578 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (soft gelatin capsules containing a new self-nanoemulsifying formulation of cyclosporin A, 200 mg) after fasting (Treatment C)
Number of subjects: 18
Study 12774949 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticonvulsants (AC Group)
Number of subjects: 100
Study 12774949 — intervention group
Group type: COMPARATOR
Intervention: No anticonvulsants (No AC Group)
Number of subjects: 100
Study 10752808 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral feed enriched with arginine, mRNA, and omega‐3 fatty acids from fish oil (Impact)
Number of subjects: 181
Study 10752808 — intervention group
Group type: COMPARATOR
Intervention: Common use, high protein control feed (Precitene Hiperproteico)
Number of subjects: 181
Study 9172210 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondirective suggestions as pretreatment (20 min tape with pain theory and coping suggestions)
Number of subjects: 48
Study 9172210 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pretreatment)
Number of subjects: 48
Study 1603650 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable pulse rate condition (randomly varying pulse rates from trial to trial)
Number of subjects: 944
Study 1603650 — intervention group
Group type: COMPARATOR
Intervention: Constant pulse rate condition (pulse rates were constant within trial blocks)
Number of subjects: 944
Study 4005120 — intervention group
Group type: EXPERIMENTAL
Intervention: 10/170 Oros oxprenolol succinate (170 mg, initial release rate 10 mg/h)
Number of subjects: 0
Study 4005120 — intervention group
Group type: EXPERIMENTAL
Intervention: 16/260 Oros oxprenolol succinate (260 mg, initial release rate 16 mg/h)
Number of subjects: 0
Study 4005120 — intervention group
Group type: COMPARATOR
Intervention: Slow Trasicor (160 mg once daily)
Number of subjects: 0
Study 4005120 — intervention group
Group type: COMPARATOR
Intervention: Trasicor (80 mg twice daily)
Number of subjects: 0
Study 30804818 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app-based intervention (treatment as usual plus five modules: psychoeducation, recognition of symptoms and prevention of relapses, problem solving, mindfulness, and contact wall)
Number of subjects: 0
Study 30804818 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study 30804818 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app-based intervention
Number of subjects: 0
Study 28853029 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) - 12 weeks, 4 x 4-min bouts at 85-95% HRmax, 3 times/week, with nutrition advice
Number of subjects: 99
Study 28853029 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT) - 12 weeks, 44 min at 60-70% HRmax, 3 times/week, with nutrition advice
Number of subjects: 99
Study 28853029 — intervention group
Group type: COMPARATOR
Intervention: Nutrition advice only
Number of subjects: 99
Study 27746007 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin and metronidazole for 5 days postoperatively
Number of subjects: 150
Study 27746007 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical-looking drugs)
Number of subjects: 150
Study 24670891 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS
Number of subjects: 38
Study 24670891 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 38
Study 22879421 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ocriplasmin
Number of subjects: 652
Study 20538819 — intervention group
Group type: EXPERIMENTAL
Intervention: CUE intervention (visually standardized, interpreted peak flow graphs)
Number of subjects: 0
Study 18166569 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy and protein diet (120% recommended average intake)
Number of subjects: 16
Study 18166569 — intervention group
Group type: COMPARATOR
Intervention: Average energy and protein diet (100% recommended average intake)
Number of subjects: 16
Study 16130424 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic-and-prophylactic care delivered at the 'Zhemchuzhina' tuberculosis sanatorium
Number of subjects: 390
Study 12860216 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 to 80 mg
Number of subjects: 2431
Study 12860216 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Number of subjects: 2431
Study 12860216 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 to 40 mg
Number of subjects: 2431
Study 12860216 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin 10 to 80 mg
Number of subjects: 2431
Study 12860216 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin
Number of subjects: 2431
Study 10651663 — intervention group
Group type: EXPERIMENTAL
Intervention: LAM-2 W (lansoprazole 30 mg b.d., amoxycillin 1 g b.d., metronidazole 500 mg b.d. for 2 weeks)
Number of subjects: 228
Study 10651663 — intervention group
Group type: EXPERIMENTAL
Intervention: LAM-1 W (lansoprazole 30 mg b.d., amoxycillin 1 g b.d., metronidazole 500 mg b.d. for 1 week and placebo)
Number of subjects: 228
Study 10651663 — intervention group
Group type: COMPARATOR
Intervention: LA-2 W (lansoprazole 30 mg b.d., amoxycillin 1 g b.d. and placebo for 2 weeks)
Number of subjects: 228
Study 9125301 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 23
Study 9125301 — intervention group
Group type: COMPARATOR
Intervention: Olive oil
Number of subjects: 23
Study 1386976 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 39
Study 1386976 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 39
Study 1386976 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 12 mg
Number of subjects: 39
Study 1386976 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 39
Study 6384452 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (1 mg/kg/day intravenously for three doses)
Number of subjects: 57
Study 6384452 — intervention group
Group type: COMPARATOR
Intervention: Control (no furosemide)
Number of subjects: 57
Study 31832291 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg twice daily orally
Number of subjects: 40
Study 31832291 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NAC)
Number of subjects: 40
Study 28667486 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff-training intervention focusing on skills for engaging service users in activities
Number of subjects: 23
Study 28667486 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 23
Study 24595923 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (100 mg, intranasal submucosal injection, 10 mL)
Number of subjects: 15
Study 24595923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 24595923 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 15
Study 24973295 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial thickness mucosal flap
Number of subjects: 22
Study 24973295 — intervention group
Group type: COMPARATOR
Intervention: Full thickness mucoperiosteal flap
Number of subjects: 22
Study 22993917 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EA)
Number of subjects: 60
Study 22993917 — intervention group
Group type: COMPARATOR
Intervention: Continuous iliofascial block (CIFB)
Number of subjects: 60
Study 19013573 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention with Okinawan vegetables for 2 weeks
Number of subjects: 45
Study 19013573 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary intervention)
Number of subjects: 45
Study 17223475 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulses of vincristine (1.5 mg/m2 weekly for 2 weeks) and dexamethasone (6 mg/m2 daily for 7 days) every 10 weeks for six cycles
Number of subjects: 2935
Study 17223475 — intervention group
Group type: COMPARATOR
Intervention: Conventional mercaptopurine and methotrexate chemotherapy only
Number of subjects: 2935
Study 17223475 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulses of vincristine and dexamethasone
Number of subjects: 2935
Study 15073858 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG
Number of subjects: 734
Study 15073858 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG plus dacarbazine
Number of subjects: 734
Study 15073858 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 734
Study 11583749 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa‐2b 1.5 microg/kg each week plus 800 mg/day ribavirin
Number of subjects: 1530
Study 9040298 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Access Health Corp HIV-1 test system
Number of subjects: 1255
Study 9040298 — intervention group
Group type: COMPARATOR
Intervention: Traditional venous blood testing
Number of subjects: 1255
Study 8200265 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (500 mg)
Number of subjects: 10
Study 8200265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3322824 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar epidural anaesthesia
Number of subjects: 38
Study 3322824 — intervention group
Group type: COMPARATOR
Intervention: Inhalational anaesthesia
Number of subjects: 38
Study 3322824 — intervention group
Group type: COMPARATOR
Intervention: Artificial ventilation
Number of subjects: 38
Study 30279345 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 11
Study 30279345 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 11
Study 30279345 — intervention group
Group type: COMPARATOR
Intervention: Vigorous-Intensity Continuous Training (VICT)
Number of subjects: 11
Study 28577672 — intervention group
Group type: EXPERIMENTAL
Intervention: Carillon Mitral Contour System (device)
Number of subjects: 0
Study 28577672 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonimplanted)
Number of subjects: 0
Study 26273747 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine plus dexmedetomidine (20 μg)
Number of subjects: 60
Study 26273747 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine alone
Number of subjects: 60
Study 23858718 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Number of subjects: 0
Study 20878665 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Group (6 weeks movement training)
Number of subjects: 27
Study 20878665 — intervention group
Group type: COMPARATOR
Intervention: Control Group (standard care)
Number of subjects: 27
Study 19406340 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZES)
Number of subjects: 50
Study 19406340 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 50
Study 19406340 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 50
Study 17332177 — intervention group
Group type: EXPERIMENTAL
Intervention: Measles-mumps-rubella vaccine
Number of subjects: 32
Study 17332177 — intervention group
Group type: EXPERIMENTAL
Intervention: Mumps vaccine
Number of subjects: 32
Study 17332177 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubella vaccine
Number of subjects: 32
Study 17332177 — intervention group
Group type: EXPERIMENTAL
Intervention: Varicella vaccine
Number of subjects: 32
Study 17332177 — intervention group
Group type: COMPARATOR
Intervention: Pre-vaccination status
Number of subjects: 32
Study 17332177 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-vaccination status
Number of subjects: 32
Study 15107189 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 45
Study 15107189 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 45
Study 15107189 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 45